News

Podcast

Putting to practice retina innovations amid a pandemic

Author(s):

Alex Delaney-Gesing

S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.

S.K. Steven Houston III, MD, speaks with Ophthalmology Times®' Sheryl Stevenson on how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.

Watch Dr. Houston's interview from the virtual 2020 ASRS meeting on how his retina practice has utilized the NGENUITY 1.4 upgrade from Alcon

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA
December 17th 2024

The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis
December 16th 2024

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis

© 2024 MJH Life Sciences

All rights reserved.